Diseño de juegos tangibles para Espacios Interactivos, orientados a formar a niños en el pensamiento lógico y computacional

Este trabajo lleva como título “Diseño de juegos tangibles para Espacios Interactivos, orientados a formar a niños en el pensamiento lógico y computacional” y se ha desarrollado en el seno del grupo de investigación GIGA (Grupo de Informática Gráfica Avanzada) Affective Lab del departamento de Informática e Ingeniería de Sistemas de la Universidad de Zaragoza. Este grupo dispone, gracias a los proyectos CeSAr y JUGUEMOS (proyecto financiado por el ministerio de Educacion Ciencia y Tecnología TIN2015-67149-C3-1R.), un espacio interactivo en el edificio Etopia de Zaragoza (Centro de Arte y Tecnología de Zaragoza) orientado al diseño y desarrollo de juegos pervasivos para niños. El objetivo general de este proyecto ha sido diseñar juegos pervasivos para el espacio JUGUEMOS con los que enseñar conceptos básicos de programación a niños en un espacio colaborativo y de manera lúdica. Para la realización de este proyecto se ha partido de una fase analítica en la cual se ha recopilado y analizado toda la información necesaria sobre los niños, los juegos y la actualidad del mercado en lo referente a interacción tangible y programación. Gracias a esta documentación se han obtenido unas conclusiones y un punto de partida fundamental para comenzar la fase de ideación y diseño, en la cual se han definido dos conceptos independientes a desarrollar paralelamente, un juego para el espacio JUGUEMOS y una ampliación de un juego ya existente en el mercado. A partir de ahí se han desarrollado paralelamente ambos juegos en un proceso iterativo hasta obtener los prototipos finales de ambos conceptos. Por último, una vez creados estos prototipos finales de ambos conceptos se realizan unas evaluaciones de ellos en el espacio JUGUEMOS y en el colegio Los Albares de la Puebla de Alfinden. Gracias a la evaluación con usuarios reales se han detectado fallos y se han propuesto posibles opciones de mejora dejando abierta la opción de mejorar estos juegos en un futuro

La Arveja - Investigación y Tecnología en el Sur de Colombia

La arveja es una de las plantas cultivadas más antiguas aprove- chadas por la humanidad. Tiene un gran potencial nutricional, debido a que es rica en proteínas. En Colombia, el cultivo de arveja es el segundo de mayor importancia después del fríjol y, el Departamento de Nariño es el mayor productor a nivel nacional como resultado de un acertado y riguroso proceso de investigación en el mejoramiento genético y en los sistemas de cultivo logrado por personas autorizadas y entidades del Estado responsables del desarrollo tecnológico. El impacto social y económico conseguido en Colombia con la in- novación en el campo de la agricultura es destacado, al haberse logrado duplicar los rendimientos por unidad de superficie y tri- plicar el área sembrada, lo mismo que la adopción por parte de pequeños productores que han hecho del cultivo, generador de ingresos, una de las causas del desarrollo de la región. La producción de arveja en Nariño por su calidad, ha conquistado el mercado nacional y los nichos de mercado de los principales almacenes de cadena bajo convenios establecidos con asociacio- nes o cooperativas departamentales. De esta manera, se ha con- tribuido a la competitividad y sostenibilidad de los sistemas de producción agrícola de la región. Esta bonanza es el resultado de un proceso de mejoramiento iniciado por el Instituto Colombiano Agropecuario (ICA) y la Corporación Colombiana de Investigación Agropecuaria (CORPOICA) que ha sido mantenido por el Grupo de Investigación en Cultivos Andinos de la Universidad de Nariño (GRICAND) que ha sabido conservar e incrementar su inventario de germoplasma de trabajo y desarrollar el mejoramiento genéti- co de la arveja, para obtener y entregar nuevas variedades de alta producción como Sureña y Alcalá. Gracias a los recursos del Sistema General de Regalías (SGR) para la ejecución del proyecto “LA ARVEJA Investigación y Tecnología en el Sur de Colombia” por el mismo grupo GRICAND se entre- gan nuevas variedades de arveja con la introducción del gen Afila que sustituye las hojas por zarcillos, reduciendo su frondosidad y facilitando su manejo en el campo, pero manteniendo el potencial productivo de las variedades comerciales en un proceso completa- mente innovador y único en Colombia. El libro que se presenta recopila los resultados de investigación del proceso de mejoramiento genético y de los experimentos relacio- nados con la adaptación y estabilidad de las nuevas variedades de arveja, obtención y manejo de la semilla de calidad, fertilización y riego en los municipios productores de Nariño. Además, expone las respectivas conclusiones de la investigación y recomendaciones técnicas validadas a la luz de las probabilidades exigidas por el método científico, constituyéndose así en una valiosa herramienta de consulta para investigadores y estudiantes y de apoyo para asis- tentes técnicos y productores

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

Objectives To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases. Methods The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed. Results A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients'' hospitalisation. Conclusions The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study

Objectives: To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases. Methods: The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed. Results: A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients' hospitalisation. Conclusions: The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.This Project has been financed by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, Gebro Pharma, Roche Farma and Sanofi Aventis

Intravitreal bevacizumab in diabetic retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 knobloch lecture

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevaci-zumab as a preoperative, adjuvant therapy before vitrectomy for prolif-erative diabetic retinopathy. Copyright © 2017 by Asia Pacific Academy of Ophthalmology

Evolving trends in the management of acute appendicitis during COVID-19 waves. The ACIE appy II study

Background: In 2020, ACIE Appy study showed that COVID-19 pandemic heavily affected the management of patients with acute appendicitis (AA) worldwide, with an increased rate of non-operative management (NOM) strategies and a trend toward open surgery due to concern of virus transmission by laparoscopy and controversial recommendations on this issue. The aim of this study was to survey again the same group of surgeons to assess if any difference in management attitudes of AA had occurred in the later stages of the outbreak. Methods: From August 15 to September 30, 2021, an online questionnaire was sent to all 709 participants of the ACIE Appy study. The questionnaire included questions on personal protective equipment (PPE), local policies and screening for SARS-CoV-2 infection, NOM, surgical approach and disease presentations in 2021. The results were compared with the results from the previous study. Results: A total of 476 answers were collected (response rate 67.1%). Screening policies were significatively improved with most patients screened regardless of symptoms (89.5% vs. 37.4%) with PCR and antigenic test as the preferred test (74.1% vs. 26.3%). More patients tested positive before surgery and commercial systems were the preferred ones to filter smoke plumes during laparoscopy. Laparoscopic appendicectomy was the first option in the treatment of AA, with a declined use of NOM. Conclusion: Management of AA has improved in the last waves of pandemic. Increased evidence regarding SARS-COV-2 infection along with a timely healthcare systems response has been translated into tailored attitudes and a better care for patients with AA worldwide

The European Solar Telescope

The European Solar Telescope (EST) is a project aimed at studying the magnetic connectivity of the solar atmosphere, from the deep photosphere to the upper chromosphere. Its design combines the knowledge and expertise gathered by the European solar physics community during the construction and operation of state-of-the-art solar telescopes operating in visible and near-infrared wavelengths: the Swedish 1m Solar Telescope, the German Vacuum Tower Telescope and GREGOR, the French Télescope Héliographique pour l'Étude du Magnétisme et des Instabilités Solaires, and the Dutch Open Telescope. With its 4.2 m primary mirror and an open configuration, EST will become the most powerful European ground-based facility to study the Sun in the coming decades in the visible and near-infrared bands. EST uses the most innovative technological advances: the first adaptive secondary mirror ever used in a solar telescope, a complex multi-conjugate adaptive optics with deformable mirrors that form part of the optical design in a natural way, a polarimetrically compensated telescope design that eliminates the complex temporal variation and wavelength dependence of the telescope Mueller matrix, and an instrument suite containing several (etalon-based) tunable imaging spectropolarimeters and several integral field unit spectropolarimeters. This publication summarises some fundamental science questions that can be addressed with the telescope, together with a complete description of its major subsystems

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

CMS physics technical design report : Addendum on high density QCD with heavy ions

Peer reviewe